Similar to some known AMPs, Spgillcin177–189 showed no anticancer activity to either the hepatoma cell line Hep G2 or the non-small lung carcinoma cell line NCI-H460 tested in this study. This evidence concerns the gene ADSL and hepatocellular carcinoma.